Trial Profile

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Etentamig (Primary) ; Iberdomide (Primary) ; ISB 2001 (Primary) ; Lenalidomide (Primary) ; Mezigdomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors AbbVie

Most Recent Events

21 Jul 2026 Number of arms changed from 15 to 21. Five experimental arms for Experimental: Substudy 5 and Experimental: Substudy 6 added to study protocol. Primary and secondary outcome measures updated. Planned number of patients also increased.
21 Jul 2026 Planned number of patients changed from 440 to 602.
21 Jul 2026 Planned End Date changed from 1 Mar 2036 to 1 Dec 2035.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com